Arcturus Therapeutics
ARCT
46 hedge funds and large institutions have $79M invested in Arcturus Therapeutics in 2016 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 11 increasing their positions, 14 reducing their positions, and 9 closing their positions.
130% more call options, than puts
Call options by funds: $848K | Put options by funds: $369K
8% less funds holding
Funds holding: 50 → 46 (-4)
21% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 14
39% less capital invested
Capital invested by funds: $131M → $79M (-$51.5M)
44% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 9
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
Top Sellers
ARCT Hedge Fund Activity: Q1 2016 in Review
46 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Arcturus Therapeutics (ARCT) for Q1 2016, worth a combined $79M — down 39% from $131M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of ARCT and 5 opened new positions — a net loss of 4 holders — while 14 trimmed existing stakes and 11 added.
The largest buyer was Franklin Resources, adding an estimated $3.89M. The largest seller was Balyasny Asset Management, cutting an estimated $2.13M.
- 46 institutional investors held Arcturus Therapeutics (ARCT) as of Q1 2016, down from 50 in Q4 2015.
- Funds reported $79M of Arcturus Therapeutics stock for Q1 2016, down 39% quarter-over-quarter.
- 5 funds opened new Arcturus Therapeutics positions in Q1 2016 and 9 closed out, a net change of -4 holders.
- The largest Arcturus Therapeutics buyer in Q1 2016 was Franklin Resources, an estimated $3.89M added.
- The largest Arcturus Therapeutics seller in Q1 2016 was Balyasny Asset Management, an estimated $2.13M sold.
Based on aggregated 13F filings for Q1 2016.